Drug intelligence / Profile preview

YB-001

Development stage: Preclinical
Lead developer: YouthBio Therapeutics

Overview

YB-001 is a preclinical drug candidate initially developed by YouthBio Therapeutics, Inc. It is currently being investigated for its potential therapeutic use in Hutchinson-Gilford progeria syndrome. The specific mechanism of action for YB-001 has not been publicly disclosed in the provided information.

Beyond the preview

Go deeper on YB-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YB-001.

Explore the full profile